Dry Eye

The company expects to launch the supplement in the US, which features a proprietary blend of ingredients including lutein, zeaxanthin isomers, curcumin and vitamin D3, under the brand name Blink NutriTears early in the third quarter of 2024.

Analysis showed that patients with dry eye had “worse sleep quality than the healthy population."

Look beyond isolated treatment of the eye to address systemic factors.

According to researchers, insights into the ocular microbiome could have implications beyond eye health.

The company said the module, which includes real-world data on more than 10 million patients, will help advance research and accelerate therapy development for dry eye disease and other ocular surface disorders.

Following the CRL from the FDA last year, Aldeyra is planning to initiate a dry eye chamber clinical trial in the first half of 2024.

A Purdue University researcher is leading a team that is creating patent-pending smart contacts for glaucoma, neovascularization and dry eyes.

The transient receptor potential melastatin 8 (TRPM8) are cold-sensitive thermoreceptors that play central role in tear film homeostasis

Cyclosporine superior to vehicle, improves corneal staining in dry eye disease

Delivered in a water-free solution, Vevye’s new formulation offers a high concentration of cyclosporine that works rapidly, has no preservatives, and rarely causes irritation

TL-925 is a first in class, topical Bruton’s tyrosine kinase (BTK) inhibitor that prevents mast cell activation and degranulation, and also blocks the cytokine-driven inflammatory response, and restores lacrimal unit homeostasis, offering the potential for disease modification

In the trial, PL9643 failed to meet co-primary and secondary endpoints.

Products under the terms of the agreement include VERKAZIA, Cationorm PLUS, VEVYE, IHEEZO, and ZERVIATE.

The recall is “due to potential safety concerns after FDA investigators found insanitary conditions.”

AR-15512, a topical transient receptor potential melastatin 8 agonist, is a first-in-class product candidate for the treatment of the signs and symptoms of dry eye disease. Alcon plans to file a New Drug Application for AR-15512 with the FDA in mid-2024.

According to the company, cyclosporine ophthalmic solution 0.1% is the first and only cyclosporine-based product for treating the signs and symptoms of dry eye disease.

According to OKYO Pharma, the first-in-human, randomized, double-masked, placebo-controlled trial of OK-101 “established a clear and informed path for further development in Phase 3 registration trials.”

The company is announcing 3 market access partnerships with PhilRx, Apollo Care, and PARx Solutions, expanding US availability of the solution.

DED incidence rates vary markedly depending on the ophthalmic practice.

The company announced plans to enroll 320 volunteers in the study. Vezocolmitide is the first drug candidate based on PolyCol, Stuart Therapeutics' patented synthesized polypeptide collagen mimetic peptide platform.

Interventional eyelid procedures enabled by TearCare technology delivered clinically and statistically significant improvements in every sign and symptom measured at every time point through 6 months.

The companies announced they will team up to enhance patient care and workflow efficiencies with a comprehensive dry eye assessment and relief platform.

According to the company, its RELIEF Phase 2b trial will evaluate the efficacy and safety of licaminlimab in moderate-to-severe dry eye disease, and further explore the potential of a genetic biomarker. Topline results are expected in mid-2024.

The company says top-line efficacy and safety data is on track for release in December of 2023.